(News Bulletin 247) – Stifel reaffirms its ‘buy’ recommendation on Novo Nordisk with a price target raised from 1,205 to 1,280 Danish kroner, ‘on the basis of very strong business momentum for the group, while catalysts significant are yet to come.
The broker raised its own estimates for the Danish pharmaceutical company, the day after it raised its annual objectives, three weeks before the presentation of its first quarter figures.
‘Based on this strong start to the year and a good trajectory for GLP-1 drugs, Novo Nordisk now sees annual objectives fully above the upper limit of its previous forecasts’, he underlines Thus.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
